DOI: 10.36347/sjams.2015.v03i04.042

Pages: 1798-1803

This study was conducted to see the perinatal transmission among HIV infected women receiving antiretroviral prophylaxis and therapy. This prospective study was conducted among women who were found to be HIV positive during antenatal screening. These women then received either anti-retroviral prophylaxis (ARV) or antiretroviral therapy (ART) according to WHO classification and CD4 count.Group-1 women receivedARV from 28 weeks of gestation with Zidovudine + Lamivudine + Nevirapine, followed by Zidovudine+ Lamivudine for 7 days postpartum. The neonate received a single dose Nevirapine syrup followed by Zidovudinefor 6 weeks. Group-2 women received ART with Zidovudine , Lamivudine and Nevirapine antenatally and thereafter. Perinatal HIV transmission was seen by DNA PCR in the babies done at 6 weeks and 6 month of age.The perinatal transmission rate was 15% in Group 1and 10% in Group 2and this difference was not significant (p=1). In Group1, the transmission rate was lower in women delivered by elective CS as compared to those delivering vaginally but the difference was not significant. In Group 2, no such trend was seen which indicated that the mode of delivery did not affect the outcome. Analysis of this small group shows a trend (statistically not significant) in reduced perinatal transmission among women on ART (due to their HIV disease state) as compared to women receiving WHO 2006 abbreviated regimen of ARV.